Sumitomo Pharma Co., Ltd.
4506.T · JPX
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | ¥119 | ¥108 | ¥106 | ¥112 |
| % Growth | 10.3% | 2.2% | -6% | – |
| Cost of Goods Sold | ¥46 | ¥44 | ¥40 | ¥41 |
| Gross Profit | ¥74 | ¥64 | ¥66 | ¥71 |
| % Margin | 61.7% | 59.2% | 62.5% | 63.1% |
| R&D Expenses | ¥9 | ¥8 | ¥13 | ¥10 |
| G&A Expenses | ¥0 | ¥0 | ¥0 | ¥0 |
| SG&A Expenses | ¥41 | ¥36 | ¥50 | ¥41 |
| Sales & Mktg Exp. | ¥0 | ¥0 | ¥0 | ¥0 |
| Other Operating Expenses | ¥0 | ¥0 | -¥12 | -¥2 |
| Operating Expenses | ¥50 | ¥44 | ¥50 | ¥50 |
| Operating Income | ¥23 | ¥20 | ¥16 | ¥21 |
| % Margin | 19.5% | 18.6% | 14.7% | 19% |
| Other Income/Exp. Net | ¥58 | -¥8 | -¥22 | ¥35 |
| Pre-Tax Income | ¥81 | ¥12 | -¥6 | ¥56 |
| Tax Expense | -¥7 | ¥1 | -¥9 | ¥3 |
| Net Income | ¥88 | ¥11 | ¥2 | ¥53 |
| % Margin | 73.6% | 10.4% | 2.3% | 47.5% |
| EPS | 220.63 | 28.21 | 6.08 | 134.53 |
| % Growth | 682.1% | 364% | -95.5% | – |
| EPS Diluted | 220.63 | 28.21 | 6.08 | 134.53 |
| Weighted Avg Shares Out | 0 | 0 | 0 | 0 |
| Weighted Avg Shares Out Dil | 0 | 0 | 0 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | ¥1 | ¥1 | ¥0 | ¥16 |
| Interest Expense | ¥0 | ¥9 | ¥7 | ¥0 |
| Depreciation & Amortization | ¥5 | ¥5 | ¥6 | ¥6 |
| EBITDA | ¥86 | ¥26 | ¥6 | ¥27 |
| % Margin | 72.3% | 24.2% | 5.3% | 24.4% |